À¶Ý®ÊÓƵ

Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
À¶Ý®ÊÓƵ

Results from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine kinase/janus kinase inhibitor, in relapsed/refractory peripheral T-cell lymphoma.

À¶Ý®ÊÓƵ

Results from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine kinase/janus kinase inhibitor, in relapsed/refractory peripheral T-cell lymphoma. Leukemia & lymphoma Horwitz, S. M., Feldman, T. A., Ye, J. C., Khodadoust, M. S., Munoz, J., Hamlin, P. A., Kim, Y. H., Wilcox, R. A., Patel, M. R., Coffey, G., Innes, A., Betz, A., Holland, J., Guzman, C. B., Smith, S. M. 2025: 1-11

Abstract

In this phase-2a study (NCT01994382), patients aged =18?years with relapsed/refractory peripheral T-cell lymphoma (PTCL; angioimmunoblastic T-cell lymphoma/T follicular helper [AITL/TFH], n?=?29); PTCL-not otherwise specified [NOS], n?=?11; and Other, n?=?25) received 30?mg oral cerdulatinib, a reversible dual inhibitor of spleen tyrosine kinase and Janus kinase, twice daily in 28-day cycles until disease progression or unacceptable toxicity. Overall response rate (ORR) was 36.2% (12 complete responses [CR],9 partial responses [PR], and 14 stable disease); median time to response was 1.9?months. ORR was 51.9% for AITL/TFH (10 CR, 4 PR) and 31.8% for Other (2 CR, 5 PR); median duration of response was 12.9 and 5.3?months, respectively. The most common grade =3 treatment-emergent adverse events were asymptomatic amylase elevation (23.1%), anemia (20.0%), and asymptomatic lipase elevation (18.5%). These data suggest clinical activity and acceptable tolerability for cerdulatinib in patients with relapsed/refractory PTCL.

View details for

View details for